Xencor has terminated developed of IL-12-Fc, a reduced potency cytokine fusion protein. #XmAb662 had been in a solid tumor basket study with #pembrolizumab.
$XNCR #biosky #biotech #immunoncology
clinicaltrials.gov/study/NCT059...